Literature DB >> 23389658

Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Rosa Resende1, Sueli C F Marques, Elisabete Ferreiro, Isaura Simões, Catarina R Oliveira, Cláudia M F Pereira.   

Abstract

Alzheimer's disease, the most prevalent age-related neurodegenerative disease, is characterized by the presence of extracellular senile plaques composed of amyloid-beta (Aβ) peptide and intracellular neurofibrillary tangles. More than 50 % of Alzheimer's disease (AD) patients also exhibit abundant accumulation of α-synuclein (α-Syn)-positive Lewy bodies. This Lewy body variant of AD (LBV-AD) is associated with accelerated cognitive dysfunction and progresses more rapidly than pure AD. In addition, it has been suggested that Aβ and α-Syn can directly interact. In this study we investigated the effect of α-Syn on Aβ-induced toxicity in cortical neurons. In order to mimic the intracellular accumulation of α-Syn observed in the brain of LBV-AD patients, we used valproic acid (VPA) to increase its endogenous expression levels. The release of α-Syn from damaged presynaptic terminals that occurs during the course of the disease was simulated by challenging cells with recombinant α-Syn. Our results showed that either VPA-induced α-Syn upregulation or addition of recombinant α-Syn protect primary cortical neurons from soluble Aβ1-42 decreasing the caspase-3-mediated cell death. It was also found that neuroprotection against Aβ-induced toxicity mediated by α-Syn overexpression involves the PI3K/Akt cell survival pathway. Furthermore, recombinant α-Syn was shown to directly interact with Aβ1-42 and to decrease the levels of Aβ1-42 oligomers, which might explain its neuroprotective effect. In conclusion, we demonstrate that either endogenous or exogenous α-Syn can be neuroprotective against Aβ-induced cell death, suggesting a cell defence mechanism during the initial stages of the mixed pathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389658     DOI: 10.1007/s11064-013-0982-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  39 in total

1.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

2.  Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures treated with amyloid-β oligomers.

Authors:  Rui O Costa; Pascale N Lacor; Ildete L Ferreira; Rosa Resende; Yves P Auberson; William L Klein; Catarina R Oliveira; Ana C Rego; Cláudia M F Pereira
Journal:  Aging Cell       Date:  2012-07-16       Impact factor: 9.304

3.  Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection.

Authors:  M C Quilty; A E King; W-P Gai; D L Pountney; A K West; J C Vickers; T C Dickson
Journal:  Exp Neurol       Date:  2005-11-28       Impact factor: 5.330

4.  Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.

Authors:  M L Kraybill; E B Larson; D W Tsuang; L Teri; W C McCormick; J D Bowen; W A Kukull; J B Leverenz; M M Cherrier
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

5.  Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.

Authors:  J Klucken; M Ingelsson; Y Shin; M C Irizarry; E T Hedley-Whyte; M Frosch; J Growdon; Pamela McLean; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2006-02-16       Impact factor: 17.088

6.  Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease.

Authors:  Cristine Alves Da Costa; Erwan Paitel; Bruno Vincent; Frédéric Checler
Journal:  J Biol Chem       Date:  2002-10-22       Impact factor: 5.157

Review 7.  Aggregation and neurotoxicity of alpha-synuclein and related peptides.

Authors:  O M A el-Agnaf; G B Irvine
Journal:  Biochem Soc Trans       Date:  2002-08       Impact factor: 5.407

8.  Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

Authors:  Pravat K Mandal; Jay W Pettegrew; Eliezer Masliah; Ronald L Hamilton; Ratna Mandal
Journal:  Neurochem Res       Date:  2006-09-01       Impact factor: 4.414

Review 9.  Examining the mechanisms that link β-amyloid and α-synuclein pathologies.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Alzheimers Res Ther       Date:  2012-04-30       Impact factor: 6.982

Review 10.  MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE.

Authors:  Nicola Origlia; Ottavio Arancio; Luciano Domenici; Shirley ShiDu Yan
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

View more
  13 in total

Review 1.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

Review 2.  Cause and consequence of Aβ - Lipid interactions in Alzheimer disease pathogenesis.

Authors:  Vijayaraghavan Rangachari; Dexter N Dean; Pratip Rana; Ashwin Vaidya; Preetam Ghosh
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-03-09       Impact factor: 3.747

Review 3.  Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Authors:  Kirsten L Viola; William L Klein
Journal:  Acta Neuropathol       Date:  2015-01-22       Impact factor: 17.088

4.  Curcumin slows the progression of Alzheimer's disease by modulating mitochondrial stress responses via JMJD3-H3K27me3-BDNF axis.

Authors:  Jingna Li; Shanshan Wang; Simiao Zhang; Dan Cheng; Xiaopeng Yang; Yutong Wang; Honglei Yin; Yajun Liu; Yanqiu Liu; Hongying Bai; Shuang Geng; Yunliang Wang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

5.  Mini review: linkage between α-Synuclein protein and cognition.

Authors:  Huda Saleh; Ayeh Saleh; Hailan Yao; Jie Cui; Yong Shen; Rena Li
Journal:  Transl Neurodegener       Date:  2015-03-28       Impact factor: 8.014

Review 6.  Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.

Authors:  Gary P Morris; Ian A Clark; Bryce Vissel
Journal:  Acta Neuropathol Commun       Date:  2014-09-18       Impact factor: 7.801

7.  New α- and γ-synuclein immunopathological lesions in human brain.

Authors:  Irina Surgucheva; Kathy L Newell; Jeffrey Burns; Andrei Surguchov
Journal:  Acta Neuropathol Commun       Date:  2014-09-11       Impact factor: 7.801

8.  Cross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study.

Authors:  Jaya C Jose; Prathit Chatterjee; Neelanjana Sengupta
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

9.  Genetic Association between Presenilin 2 Polymorphisms and Alzheimer's Disease and Dementia of Lewy Body Type in a Japanese Population.

Authors:  Ayako Suzuki; Nobuto Shibata; Koji Kasanuki; Tomoyuki Nagata; Shunichiro Shinagawa; Nobuyuki Kobayashi; Tohru Ohnuma; Yoshihide Takeshita; Eri Kawai; Toshiki Takayama; Kenya Nishioka; Yumiko Motoi; Nobutaka Hattori; Kazuhiko Nakayama; Hisashi Yamada; Heii Arai
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-03-16

Review 10.  Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?

Authors:  Debby Van Dam; Yannick Vermeiren; Alain D Dekker; Petrus J W Naudé; Peter P De Deyn
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.